Emcure Pharmaceuticals credit ratios

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025

1,204	1,204	732
1,057	1,057	490
0.24×	0.24×	0.16×
0.21×	0.21×	0.11×
0.65×	0.65×	0.50×
0.53×	0.57×	0.33×
10.09×	10.09×	6.20×
19.5%	19.5%	13.6%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

EMCURE₹1,865.00

Emcure Pharmaceuticals Ltd.

· Pharma & Health

₹ CrorePeersMANKIND ALKEM TORNTPHARM ERIS GRANULES CONCORDBIO INDGN CAPLIPOINTMcap ₹35,359 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Total Debt	731.7	1,204.1	1,204.1
Net Debt	490.4	1,056.6	1,056.6
Total Debt/Equity	0.16	0.24	0.24
Net Debt/Equity	0.11	0.21	0.21
Total Debt/EBITDA	0.50	0.65	0.65
Net Debt/EBITDA	0.33	0.57	0.53
Interest Coverage (EBIT/Interest)	6.20	10.09	10.09
Total Debt/Total Capital %	13.62	19.48	19.48

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.